COSM
****Sponsored by Primetime Profiles, LLC
Zacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis
Zacks projects Cosmos Health revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026
Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH)
READ THE INVESTOR PRESENTATION HERE
________________________
Hello Everyone,
We are back with something explosive sitting under .50 with explosive bounce potential.
Pull up COSM right now.
Cosmos is a vertically integrated healthcare group with operations spanning pharmaceuticals, nutraceuticals, pharmaceutical distribution, manufacturing, and an expanding portfolio of technology- and services-oriented assets. Over the past several years, the company has deliberately combined stable, cash-generating businesses in Europe with targeted acquisitions and internal research initiatives aimed at improving revenue quality and unlocking higher-growth opportunities. This strategy has created a diversified platform designed to balance recurring commercial revenues with higher-margin and higher-upside growth drivers.
Just yesterday Zacks Investment Research highlighted Cosmos Health’s diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-enabled initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation.
Key Highlights from Zacks Small-Cap Research Coverage
Initiation of Coverage with $4.50 Per Share Valuation
Zacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis, reflecting projected revenue growth, improving gross margins, and a modeled transition toward positive free cash flow over time.
Valuation Methodology
Zacks applied a five-year discounted cash flow framework using a 20% discount rate, reflecting the Company’s small-cap profile and execution risk. The model assumes moderate near-term revenue growth, accelerating in later years, steady improvement in free cash flow margins, and a 2% terminal growth rate.
Strong Revenue Growth Outlook
Zacks projects Cosmos Health revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with further expansion to over $130 million by 2027, driven by higher-margin pharmaceutical products, branded nutraceuticals, and technology-enabled services.
Vertically Integrated Healthcare Platform
The report highlights Cosmos Health’s vertically integrated operating model, spanning pharmaceutical distribution, GDP-compliant wholesale operations, GMP-certified manufacturing, proprietary nutraceutical brands, telehealth services, and AI-enabled research and development.
U.S. Market Entry
Zacks references Cosmos Health’s expansion into the United States market, highlighted by the acquisition of ZipDoctor, a U.S.-based telehealth subscription platform providing direct-to-consumer access. The report also notes the launch of Sky Premium Life in the U.S. nutraceutical market.
Advancing R&D Pipeline
Zacks references Cosmos Health’s development programs, including CCX0722 for obesity and weight management, as well as additional repurposed compounds targeting multiple sclerosis, allergies, and oncology-related indications, with projects advancing toward clinical and regulatory milestones. These R&D efforts reflect the Company’s focus on identifying and progressing candidates that address large disease markets.
AI-Driven Innovation via Cloudscreen
Zacks identifies the acquisition of Cloudscreen, an AI-enabled drug repurposing and R&D platform, as a key technology supporting Cosmos Health’s research and development activities. The platform uses in silico screening and multimodal biochemical data to identify potential new therapeutic uses for existing compounds, with the goal of shortening development timelines, reducing discovery costs, and supporting potential licensing or development outcomes.
Digital Assets and Blockchain Strategy
The report notes that Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH), supported by a disclosed financing facility of up to $300 million. Zacks also references the Company’s strategic partnership with Prime Ledger LLC to manage digital assets and explore tokenization of intellectual property assets.
Improving Financial Performance and Margin Expansion
Zacks highlights Cosmos Health’s record third quarter of 2025, which included double-digit year-over-year revenue growth, significantly higher gross profit, and improved adjusted EBITDA, reflecting operational execution and a shift toward higher-margin activities.
Greg Siokas, CEO of Cosmos Health, stated: “We are pleased to see Zacks Small-Cap Research initiate coverage of Cosmos Health and recognize the transformation we have been executing across our organization. This coverage underscores the strength of our vertically integrated model, our accelerating revenue growth, and the strategic importance of our investments in AI-driven drug repurposing, proprietary pharmaceutical and nutraceutical brands, and digital health services. As we continue to scale higher-margin products, advance our R&D pipeline, and improve operational efficiency, we believe Cosmos Health is entering an important inflection point with substantial long-term value creation potential for our shareholders.”
At the core of the business, Cosmos owns established pharmaceutical brands such as C-Sept and C-Scrub, alongside nutraceutical brands including Sky Premium Life and Mediterranation. These brands are supported by Cosmofarm, the company’s GDP-compliant distribution and sourcing arm, which services more than a thousand pharmacies and maintains a broad supplier network. The group also operates GMP-certified manufacturing facilities and wholesale operations, enabling tight control across the value chain. This vertically integrated structure provides recurring revenue, operational resilience, and reduced execution risk when launching new consumer healthcare products, while allowing management to pursue multiple, complementary revenue streams through proprietary brands, contract manufacturing, and distribution.
In parallel, Cosmos has expanded its footprint into higher-growth markets and channels. The acquisition of ZipDoctor established a direct-to-consumer telehealth platform in the United States, creating a services-based revenue stream while providing a scalable channel for cross-selling nutraceutical and over-the-counter products. This expansion has been complemented by the launch of Sky Premium Life in the U.S. nutraceutical market, strengthening the company’s presence in one of the world’s largest consumer health markets. Together, these initiatives broaden Cosmos’s commercial reach while deepening engagement with end consumers.
The company has also invested meaningfully in advancing its research and development capabilities. Its development pipeline includes CCX0722 for obesity and weight management, as well as additional repurposed drug candidates targeting multiple sclerosis, allergic conditions, and oncology-related indications. These programs reflect a focused strategy of identifying compounds with established safety profiles and advancing them toward clinical and regulatory milestones in large, underserved disease markets. Supporting this effort is the acquisition of Cloudscreen, an AI-enabled drug repurposing and discovery platform that leverages in silico screening and multimodal biochemical data to accelerate target identification, shorten development timelines, and reduce discovery costs. This technology-driven approach positions Cosmos to pursue higher-margin licensing, partnering, or development outcomes over time.
Recent financial performance underscores the progress of this strategy. The company reported its strongest third quarter on record in 2025, delivering double-digit year-over-year revenue growth alongside meaningful improvements in gross profit and adjusted EBITDA. These results indicate that the ongoing shift toward higher-margin products, services, and technology assets is beginning to be reflected in the financials. Looking ahead, management expects continued revenue expansion over the next several years, driven by growth in branded pharmaceuticals, nutraceuticals, telehealth services, and technology-enabled R&D initiatives.
Finally, Cosmos has demonstrated a willingness to explore innovative capital allocation and infrastructure strategies. The company has implemented a digital asset allocation program that includes the purchase of Ethereum, supported by a disclosed financing facility of up to $300 million. In addition, a strategic partnership with Prime Ledger LLC is intended to support digital asset management and explore the potential tokenization of intellectual property assets. These initiatives highlight management’s broader focus on optionality, innovation, and long-term value creation across both traditional healthcare and emerging digital frameworks.
NEWS
20 hours ago
20 hours ago
Jan 5, 2026
Jan 5, 2026
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
Dec 24, 2025
Cosmos Health is Forcing the Market to Reframe the Conversation
Dec 19, 2025
Dec 3, 2025
Dec 3, 2025
Dec 2, 2025
Dec 2, 2025
Management
Sincerely,
